ORIGINAL ARTICLE

Human papillomavirus associated with oesophageal cancer

T Matsha, R Erasmus, A B Kafuko, D Mugwanya, A Stepien, M I Parker for the CANSA/MRC Oesophageal Cancer Research Group

J Clin Pathol 2002;**55**:587–590

See end of article for authors' affiliations

Correspondence to: Professor M I Parker, Division of Medical Biochemistry, UCT, Faculty of Health Sciences, Observatory, 7925 South Africa; mparker@curie.uct.ac.za

Accepted for publication 15 April 2002

Aim: To study the prevalence and the different types of human papillomavirus (HPV) in patients with oesophageal cancer from a high risk area of South Africa (Transkei).**Methods:** DNA samples from 50 paraffin wax embedded tissue sections were analysed by nested polymerase chain reaction (PCR) using the degenerate HPV L1 consensus primer pairs MY09/MY11 and GP5+/GP6+. Positive PCR samples were subjected to DNA sequence analysis.**Results:** HPV DNA was detected in 23 of the 50 samples. Sequence analysis revealed that most patients (11) harboured DNA to HPV type 11, whereas other types included DNA HPV type 39 (seven patients), type 16 (two patients), and type 52 (one patient). HPV type 39 has not previously been shown to be associated with oesophageal cancer. In contrast to earlier studies that have found HPV type 16 to be more frequently associated with oesophageal cancer, HPV type 11 was the predominant subtype in this study.**Conclusions:** The high frequency of occurrence of HPV in oesophageal tumours (23 of 50 patients; 46%) implicates HPV as one of the possible aetiological factors in this disease. The finding that the low risk HPV subtypes predominate indicates that transformation may be effected via the E6 and E7 proteins.

Human papillomavirus (HPV) has been implicated as a causative agent in a variety of human squamous cell carcinomas, including those of the skin, cervix, anogenital region, upper respiratory tract, and digestive track. To date, more than 70 different HPV types have been identified; some of which are frequently associated with cancers and are considered high risk HPVs (types 16 and 18), whereas others give rise to warts and benign lesions and are considered low risk (types 6, 11, and 33).

One of the characteristic features of oesophageal cancer is its tremendous variation in both geographical and ethnic incidence. The areas in the world that have a high incidence of oesophageal cancer include the Transkei in South Africa, the area around the shores of the Caspian Sea in northern Iran, the Henan and Shanxi provinces of China, South America, and the southern areas of France.^{1–4} Oesophageal cancer is the most common cancer among black South African men, where the lifetime risk of developing this cancer is one in 39, and is second only to carcinoma of the cervix in black women.⁵ There appears to be a distinct racial variation in the types of oesophageal cancer, with a predominance of squamous cell cancer among blacks, whereas adenocarcinoma is more frequently seen in whites.⁶

"The association of certain types of HPV primarily with normal tissue or benign lesions, as opposed to the cancer associated types, has led to the concept of low and high oncogenic risk HPVs"

Oesophageal cancer has been poorly studied, but a variety of risk factors such as smoking, alcohol consumption, and nutritional deficiencies have been implicated in the aetiology of the disease. In developed countries, heavy alcohol consumption and cigarette smoking, especially in combination, are the most common risk factors.^{7,8} In contrast, in developing countries, nutritional deficiencies, tobacco and betelnut chewing, and exposure to nitrosamines are also of major importance.^{4,7,8}

HPV was implicated for the first time in the pathogenesis of oesophageal cancer in a study reported in 1982.⁹ These organisms are small non-enveloped DNA viruses classified as belonging to the Papovaviridae family, and more than 70 papillomavirus types have been identified on the basis of sequence divergence.^{10–11} The association of certain types of HPV primarily with normal tissue or benign lesions, as opposed to the cancer associated types, has led to the concept of low and high oncogenic risk HPVs.^{10–12}

Studies on the presence of HPV in oesophageal cancer have generated conflicting results, with the prevalence rates ranging from 0% to 71%.¹³ These differences probably result from variations in the specificity and sensitivity of the analytical techniques used. Compared with other techniques, the polymerase chain reaction (PCR) is a simple, rapid, and sensitive method for the detection of HPV DNA in tissue samples. Furthermore, the use of consensus primers is an advantage in PCR based studies because these primers can detect a wide spectrum of HPV types.¹⁴

In our study, we have determined the incidence and type of HPV in tumours from patients with oesophageal cancer in the Transkei, a high risk area for this cancer, using nested PCR with degenerate HPV L1 consensus primers that can detect a wide variety of genotypes. The major HPV detected in these patients was HPV-11.

MATERIALS AND METHODS

Tissue collection

The Umtata General Hospital is a 1000 bed facility and the major tertiary care centre for the Transkei, to which all cases of oesophageal cancer are referred. Fifty paraffin wax embedded blocks of histologically confirmed squamous cell carcinoma of

Abbreviations: HPV, human papillomavirus; PCR, polymerase chain reaction

Table 1 Primers used in PCR amplification of human papillomavirus DNA showing the corresponding annealing temperatures and PCR product sizes

Primers	Annealing temperature	PCR product
MY09: 5'-CGTCCMARRGGAWACTGATC-3'	55°C	450 bp
MY11: 5'-GCMCAGGGWCATAAATGG-3'	55°C	450 bp
GP5+: 5'-TTTGTACTGTGGTAGATAC TAC-3'	40°C	150 bp
GP6+: 3'-CTTAT ACTAAATGTCAAATAAAAG-5'	40°C	150 bp

M, A+C; R, A+G; W, A+T; Y, C+T. PCR was first performed using the degenerate MY09/MY11 primer set, following by nested PCR with the GP5+/GP6+ set.

Figure 1 Nested PCR amplification. DNA was isolated from biopsies obtained from patients with oesophageal cancer and subjected to nested PCR using the conditions shown in table 1 and in the materials and methods section. Lanes 1 and 2 are the negative controls and lane 3 is a positive control derived from a patient with cervical carcinoma known to be human papillomavirus (HPV) positive. The samples in lanes 4, 6, 7, and 10 were positive for HPV, whereas the samples in lanes 5, 8, 9, 11, and 12 were negative for HPV.

the oesophagus were randomly chosen from archival material in the department of anatomical pathology of the Umtata General Hospital during the period 1995 to 1998. The demographic data of each of the patients were retrieved from their respective records. The biopsies were taken from black patients who presented clinically with varying degrees of dysphagia. The mean age of patients was 57.5 years (range, 36–80 years) with a male to female ratio of 1.4 : 1. Clinically, all of the patients presented with dysphagia and histopathological analysis of their biopsies confirmed the presence of squamous cell carcinoma of the oesophagus. Samples were analysed for the presence of HPV DNA using PCR under the conditions described in table 1.

DNA extraction

DNA was isolated from the biopsies using standard DNA isolation procedures. Care was taken to avoid cross contamination of samples during all steps of the procedure. The quality of the DNA was checked by agarose gel electrophoresis. DNA from formalin fixed, paraffin wax embedded tissue sections was prepared for PCR essentially as described previously.¹⁵ Three 10 µm thick sections from each of the 50 blocks were placed into 1.5 ml microcentrifuge tubes and dewaxed with sequential washes of xylene and 95% ethanol. Pellets were dried and digested overnight at 37°C with 100 µg/ml proteinase K in 50mM Tris/HCl (pH 8.0), 1mM EDTA, and 0.5% Tween 20. The enzyme was inactivated at 95°C for 10 minutes, and the absorbance of an aliquot of each sample was measured at 260 nm and 280 nm to measure the amount of the DNA before storage at –20°C. Procedures to prevent specimen contamination

and PCR carry over were rigorously observed. A new microtome blade was used for each biopsy specimen, with DNA extraction and PCR analysis being carried out in small batches.

PCR amplification

The degenerate MY09/MY11 primer set was synthesised on a Beckman Oligo 1000 DNA synthesiser (Beckman, California, USA). The primer set (table 1) was capable of amplifying a wide spectrum of HPV types to produce a PCR product of 450 bp.^{15–17} The amplification mixture consisted of 1× PCR buffer, (10mM Tris/HCl, pH 8.3, 50mM KCl, and 1.5mM MgCl₂), 200µM of each dNTP, 100 pmol of each primer, 2.5 units of Taq DNA polymerase (Roche Biochemicals) and 500 ng of DNA in a final volume of 50 µl. Forty amplification cycles were completed in an Eppendorf Mastercycler as follows: one minute at 94°C, one minute at 55°C, and 1.5 minutes at 72°C. The initial denaturation step was for three minutes at 94°C and the final extension step was prolonged to five minutes at 72°C. Each batch of samples included negative controls containing water and positive control DNA from an HPV positive cervical carcinoma. PCR products were analysed on a 2% agarose gel and visualised by ethidium bromide staining.

The GP5+/GP6+ primer set is a non-degenerate primer set (table 1) that detects a wide range of HPV types using a lower annealing temperature during PCR and produces a PCR product of approximately 150 bp.^{15–17} The PCR mixture consisted of 1× PCR buffer, 200µM of each dNTP, 50 pmol of each primer, 2.5 units of Taq polymerase (Roche, Mannheim, Germany), and 500 ng of DNA in a final, volume of 50 µl. Forty amplification cycles were completed in an Eppendorf Mastercycler according to the following protocol: initial denaturation was for five minutes at 94°C, followed by denaturation for one minute at 94°C, annealing for two minutes at 40°C, extension for 1.5 minutes at 72°C, and a final extension step of five minutes at 72°C.

The WD66, WD67, WD72, WD76, and WD154 primers are consensus primers that target the E6 and E7 transforming genes.

Sequencing of PCR products

To identify the HPV types, all the positive PCR products were subjected to direct DNA sequence analysis using the T7 Sequenase version 2.0 DNA PCR product sequencing kit (Amersham, Little Chalfont, Buckinghamshire, UK). The nucleotide sequences were subsequently subjected to Basic Local Alignment Search (BLAST), which is a set of similarity search programmes designed to explore all of the available sequence databases (ncbi.nih.gov).

RESULTS

PCR using the MY09/MY11 primer pair resulted in very weak amplification of the appropriately sized DNA fragment, whereas subsequent PCR with the internal primer pair GP5+/GP6+ yielded intense bands of the correct size (150 bp). Of the 50 specimens tested, 23 were positive for HPV, as seen by

Table 2 Frequency of HPV types in oesophageal cancer biopsies

HPV type	No. of patients
11	11
39	7
16	2
52	1
Unknown	2
Total	23

DNA was isolated from oesophageal cancer biopsies and subjected to PCR amplification using the primers indicated in table 1 and under the conditions described in the material and methods section.

Table 3 Correlation between the presence of HPV subtype and the histopathological data in SCC of the oesophagus

No. of patients	HPV type	Histopathology
8	11	SCC, keratinising type
3	11	SCC, papillary keratinising type
2	16	SCC, non-keratinising type
1	52	SCC, non-keratinising type
7	39	SCC, keratinising
2	Unknown	SCC, keratinising

HPV, human papillomavirus; SCC, squamous cell carcinoma.

the presence of the 150 bp PCR fragment (fig 1). All samples that were positive with the L1 primers also yielded a band of the correct size with the E6 and E7 primers (data not shown).

The PCR products were subjected to DNA sequence analysis and aligned with the known HPV sequences in the DNA database using BLAST (National Institutes of Health). The biopsies were shown to contain DNA to HPV types 11, 16, 39, and 52. The low risk HPV-11 was the most common subtype (48%) whereas the intermediate and high risk HPV-52 and HPV-16 occurred at a much lower frequency (13%) (table 2).

The correlations between the histological data and the HPV subtype are shown in table 3.

DISCUSSION

Several studies during the past two decades have shown the presence of HPV in DNA isolated from patients with oesophageal cancer.^{3 6 18–34} Studies have generated conflicting and often contradictory data, which may be attributed to the geographical location with respect to either low or high incidence areas.^{20 34} In addition, variations in the prevalence rates of HPV from the same geographical areas have also been reported. For example, the presence of HPV DNA has been confirmed in 23.4% of patients with oesophageal cancer in China,²³ whereas another study carried out in the same area²⁴ found no evidence of HPV DNA. Similarly, prevalence rates of 50% and 23% have been reported in patients with oesophageal cancer from Australia; in both instances the same technique was used.^{25 26}

In South Africa, squamous cell carcinoma of the oesophagus is the most common cancer among black men. In 1989, Sagar reported the incidence of oesophageal cancer to be nearly 400/100 000 in the age group 35–65 years.⁴ Various studies have reported the existence of high and low incidence areas of oesophageal cancer in Transkei. Rose,³⁵ using the Bantu Cancer Registry, reported that the Lusikisiki and Bizana districts in northeast Transkei had lower incidence rates (8/100 000 and 3/100 000, respectively) than the southwestern districts, of Butterworth and Centane, which had incidences of 103/100 000 and 54/100 000, respectively.³⁵

The earlier studies that associated HPV with 30% of cases of oesophageal cancer in South Africa used immuno-

-histochemistry.²⁰ Subsequent studies have reported prevalence rates ranging between 17% and 71%,^{3 28 29 32} supporting the notion that HPV infection may be an integral part of a multistep process leading to oesophageal cancer in high risk areas. However, none of these studies targeted the Transkei region of South Africa, a region with a very high incidence of oesophageal cancer. In our current study, the prevalence of HPV infection was found to be very high in that 46% of patients were HPV positive, supporting the earlier findings that HPV may play an important role in the development of oesophageal cancer in South Africa.^{3 30}

Several PCR based studies have reported on the presence of HPV in oesophageal cancer, although the detection rates differ between these studies.^{3 19–21 27–31} A variety of factors, mainly technical, may account for the observed differences in these studies.

Consensus primers have an advantage in PCR studies because they can detect a wide spectrum of HPV types, including novel types. The HPV E1 and L1 genes are suitable targets for consensus primers as long as these genes are not lost or disrupted after viral integration. In contrast, the E6 and E7 genes are thought to be retained in all carcinomas but are too variable to be targeted with consensus primers.^{10 12 36 37} Studies using paraffin wax embedded tissue sections resulted in successful amplification of several genes, ruling out the possibility that tissue fixation or the age of the blocks might affect the results of the PCR. Nested PCR with the MY09/MY11 and GP5+/GP6+ primers was sufficiently sensitive for the detection of HPV in paraffin wax embedded biopsies in our study.

"We also detected HPV type 39, which has never before been shown to be present in oesophageal cancer"

The earlier studies discussed above have shown that HPV types 16 and 18 were more commonly detected in oesophageal cancer. In our study, we found HPV type 16 DNA to be present in only two of the 50 samples, whereas HPV type 18 DNA was not detected. HPV type 52 DNA was present in only one sample whereas HPV type 11 was the most predominant. Chang and colleagues²³ also detected HPV-6 and HPV-11 in oesophageal cancer biopsies by in situ hybridisation using a mixed HPV6/11 probe. HPV-6 and HPV-11 are generally found in benign genital condylomata. These two subtypes also account for almost all cases of juvenile onset and adult onset respiratory papillomatosis.^{38 39} Although found almost exclusively in benign lesions, these HPV subtypes have occasionally been detected in malignant lesions. One study has shown that women with a history of condylomata acuminata had a 3.8-fold increased incidence of carcinoma in situ compared with the total female population residing in the same city.⁴⁰ HPV type 11 has been implicated in the malignant progression of laryngopharyngeal lesions,⁴¹ cancer of the anus,⁴² and penile carcinoma.⁴³ We also detected HPV type 39, which has never before been shown to be present in oesophageal cancer. According to sequence comparison data, HPV-39 most closely resembles HPV-18 and is phylogenetically classified together with HPV-45 in the mucogenital high risk group.^{44 45} These HPVs have been detected in a disproportionately high percentage of rapidly progressive invasive cervical carcinomas. HPV-39 has been detected in erythroplasia of Queyrat,⁴⁶ a carcinoma in situ that mainly occurs on the glans, the prepuce, or the urethral meatus of elderly men.

In conclusion, a potential role of HPV in the development of oesophageal cancer has emerged as a result of the HPV-like histological changes in the mucosa of patients with oesophageal cancer and the presence of HPV antigens in tumours. Although various types of HPV have been detected by PCR amplification, clear evidence for a role in oesophageal cancer is still lacking.

Take home messages

- The high frequency of occurrence of human papillomavirus (HPV) in oesophageal tumours (23 of 50 patients; 46%) in patients from the Transkei region of South Africa implicates HPV as one of the possible aetiological factors in this disease, although definite proof is still lacking
- The predominance of the low risk HPV subtypes indicates that transformation may be effected via the E6 and E7 proteins

The high prevalence of HPV DNA in oesophageal cancer in patients from the Transkei region of South Africa provides further evidence for a role of HPV in this cancer.

ACKNOWLEDGEMENTS

This work was supported by grants from the South African Medical Research Council, the Cancer Association of South Africa, the THRIP Programme of the National Research Foundation, the University of Cape Town, and the University of Transkei.

Authors' affiliations

T Matsha, M I Parker, Department of Medical Biochemistry, Faculty of Health Sciences, University of Cape Town, Observatory, 7925 South Africa

R Erasmus, A Stepien, Department of Pathology, University of Transkei, Umtata, 5100 South Africa

A B Kafuko, D Mugwanya, Department of Thoracic Surgery, University of Transkei

REFERENCES

- 1 **Parkin DM**, Laara E, Muir CS. Estimates of the world-wide frequency of sixteen major cancers in 1980. *Int J Cancer* 1988;**41**:184-97.
- 2 **Munoz N**. Epidemiological aspects of oesophageal cancer. *Endoscopy* 1993;**25**(suppl):609-12.
- 3 **Togawa K**, Jaskiewicz K, Hiroshi T. Human papilloma virus sequences in esophagus squamous cell carcinoma. *Gastroenterology* 1994;**107**:128-36.
- 4 **Sagar PM**. Aetiology of cancer of the oesophagus: geographical studies in the footsteps of Marco Polo and beyond. *Gut* 1989;**30**:561-4.
- 5 **Chalasani N**, Wo JM, Waring JP. Racial differences in the histology, location and risk factors of esophageal cancer. *J Clin Gastroenterol* 1998;**26**:11-13.
- 6 **Sitas F**, Madhoo J, Wessie J eds. *Incidence of histologically diagnosed cancer in South Africa*. Johannesburg: South African Institute for Medical Research, 1998.
- 7 **Stemmermann G**, Heffelfinger SC, Noffsinger A, et al. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumour suppressor genes, and growth factors. *Hum Pathol* 1994;**25**:968-81.
- 8 **Day NE**, Varghese C. Oesophageal cancer. *Cancer Surv* 1994;**19**:20:43-54.
- 9 **Syrjanen KJ**. Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. *Arch Geschwulstforsch* 1982;**52**:283-92.
- 10 **Villa LL**. Human papillomaviruses and cervical cancer. *Adv Cancer Res* 1997;**71**:321-41.
- 11 **de Roda Husman A**, Walboomers JMM, van den Brule AJC, et al. The use of general GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. *J Gen Virol* 1995;**76**:1057-62.
- 12 **Turek LP**. The structure, function and regulation of papilloma viral genes in infection and cervical cancer. *Adv Virus Res* 1994;**44**:305-57.
- 13 **Sur M**, Cooper K. The role of the human papillomavirus in esophageal cancer. *Pathology* 1998;**30**:348-54.
- 14 **van den Brule AJV**, Snijders PJF, Meijer CJLM, et al. PCR-based detection of genital HPV genotypes: an update and future perspectives. *Papillomavirus Report* 1993;**4**:95-9.
- 15 **Qu W**, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. *J Clin Microbiol* 1997;**35**:1304-10.
- 16 **Baay MFD**, Quint WGU, Koudstaal J, et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. *J Clin Microbiol* 1996;**34**:745-7.
- 17 **ZehBe I**, Wilander E. Two consensus primer systems and nested polymerase chain reaction for human papillomavirus detection in cervical biopsies: a study of sensitivity. *Hum Pathol* 1996;**27**:812-15.
- 18 **Loke SL**, Ma L, Wang M, et al. Human papillomavirus in oesophageal squamous cell carcinoma. *J Clin Pathol* 1990;**43**:909-12.
- 19 **West AB**, Soloway GN, Lizararaga G, et al. Type 73 human papillomavirus in esophageal squamous cell carcinoma. *Cancer* 1996;**77**:2440-4.
- 20 **Poljak M**, Cerar A, Seme K. HPV infection in esophageal carcinomas: a study of 121 lesions using multiple broad spectrum polymerase chain reactions and literature review. *Hum Pathol* 1998;**29**:266-71.
- 21 **Miller BA**, Davidson M, Myerson D, et al. Human papillomavirus type 16 DNA in esophageal carcinomas from Alaska natives. *Int J Cancer* 1997;**71**:218-22.
- 22 **Chang F**, Syrjanen S, Shen Q, et al. Human papillomavirus involvement in esophageal precancerous lesions and squamous cell carcinomas as evidenced by microscopy and different DNA techniques. *Scand J Gastroenterol* 1992;**27**:553-63.
- 23 **Chang F**, Syrjanen S, Shen Q, et al. Screening for human papillomavirus infections in esophageal squamous cell carcinomas by in situ hybridization. *Cancer* 1993;**72**:2525-30.
- 24 **Lu S**, Luo F, Li H. Detection of HPV in esophageal squamous cell carcinoma and adjacent tissue specimen in Linxian. *Chung Hua Chung Lai Tsa Chih* 1995;**17**:321-4.
- 25 **Kulski J**, Demeter T, Sterrett GF, et al. Human papillomavirus DNA in esophageal carcinoma. *Lancet* 1986;**11**:683-4.
- 26 **Kulski JK**, Demeter T, Mutavdzic S. Survey of histologic specimens of human cancer for human papillomaviruses type 6, 11, 16, 18 by filter in situ hybridisation. *Am J Clin Pathol* 1990;**94**:566-70.
- 27 **Kiyabu MT**, Shibata D, Arnheim N, et al. Detection of human papillomavirus in formalin fixed invasive squamous carcinomas using the polymerase chain reaction. *Am J Surg Pathol* 1989;**13**:221-4.
- 28 **Poljak M**, Cerar A. Human papillomavirus type 16 DNA in esophageal squamous cell carcinoma. *Anticancer Res* 1993;**13**:2113-16.
- 29 **Williamson AL**, Jaskiewicz K, Gunning A. The detection of human papillomavirus in esophageal lesions. *Anticancer Res* 1991;**11**:263-5.
- 30 **Cooper K**, Taylor L, Govind S. HPV DNA in esophageal carcinoma in South Africa. *J Pathol* 1995;**175**:273-7.
- 31 **Turner JR**, Shen LH, Crum CP, et al. Low prevalence of human papillomavirus infection in esophageal squamous cell carcinomas from North America: analysis by a highly sensitive and specific polymerase chain reaction-based approach. *Hum Pathol* 1997;**28**:174-8.
- 32 **de Villiers EM**, Lavergne D, Chang F, et al. An interlaboratory study to determine the presence of human papillomavirus DNA in esophageal carcinoma from China. *Int J Cancer* 1999;**81**:225-8.
- 33 **Lavergne D**, de Villiers EM. Papillomavirus in esophageal papillomas and carcinomas. *Int J Cancer* 1999;**80**:681-4.
- 34 **Suzuk L**, Noffsinger AE, Hui YZ, et al. Detection of human papillomavirus in esophageal squamous cell carcinoma. *Cancer* 1996;**78**:704-10.
- 35 **Rose EF**. Esophageal cancer in the Transkei, 1955-1969. *J Natl Cancer Inst* 1973;**51**:7-16.
- 36 **Howley PM**. Mechanistic role for human papillomaviruses in human cancers. In: Fortner JG, Rhoads J eds. *Advances in Cancer Research*. Philadelphia: JB Lippincott, 1994: 174-80.
- 37 **Galloway DA**, McDougall JK. Human papillomaviruses and carcinomas. *Adv Virus Res* 1989;**37**:125-71.
- 38 **Mounts P**, Shah KV, Kashima H. Viral etiology of juvenile and adult onset squamous papilloma of the larynx. *Proc Natl Acad Sci U S A* 1982;**79**:5425-9.
- 39 **Orth G**, Faure M, Croissant O. Characterization of a new type of human papilloma virus that causes skin warts. *J Virol* 1977;**24**:108-20.
- 40 **Chuang TY**, Perry HO, Kurkland LT, et al. Condyloma acuminatum in Rochester, Minn, 1950-1978. Epidemiology and clinical features. *Arch Dermatol* 1984;**120**:469-75.
- 41 **Zarod AP**, Rutherford JD, Corbitt G. Malignant progression of laryngeal papilloma associated with human papillomavirus type 6 (HPV 6) DNA. *J Clin Pathol* 1988;**41**:280-3.
- 42 **Zemstov A**, Koss W, Dixon L. Anal verrucous carcinoma associated with human papillomavirus 11: magnetic resonance imaging and flow cytometry evaluation. *Arch Dermatol* 1992;**126**:564-5.
- 43 **Dianzani C**, Bucci M, Pierangeli A, et al. Association of human papillomavirus type 11 with carcinoma of the penis. *Urology* 1998;**51**:1046-8.
- 44 **Van Ranst M**, Kaplan JB, Burk RD. Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. *J Gen Virol* 1992;**73**:2653-60.
- 45 **Volpers C**, Streeck RE. Genome organization and nucleotide sequence of human papillomavirus type 39. *Virology* 1991;**181**:419-23.
- 46 **Wieland U**, Jurk S, Weißenborn S, et al. Erythroplasia of Queyrat: confection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. *J Invest Dermatol* 2000;**115**:396-401.